Viridis BioPharma Receives Approval for NIMBUS Foam Dressings from India FDA
Quick-Med Licensing Partner to Manufacture and Sell NIMBUS Foam Dressings in India
GAINESVILLE, Fla., Feb. 14, 2012 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCQB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has amended the license previously granted to Viridis BioPharma to include a new antimicrobial polyurethane foam dressing that utilizes Quick-Med's proprietary NIMBUS® technology and that Viridis has received approval from the Food and Drug Administration of India to manufacture and market the dressings. This is the first of several NIMBUS advanced wound care formats that are in development.
Viridis BioPharma, an India-based manufacturer and marketer of medical devices, plans to commercialize a broad line of wound care products that incorporate Quick-Med's unique NIMBUS antimicrobial technology including gauze pads, gauze rolls and foam dressings, under the trade name of Microgauze™ and Microfoam™ wound dressings. Viridis has completed a manufacturing expansion to produce the new dressings and plans to have the dressings on the market before the end of the second quarter of 2012.
Laboratory testing has demonstrated that Microfoam is highly effective against even the most difficult Gram-negative species of pathogenic bacteria. Additionally, Viridis has conducted a pilot clinical trial in Mumbai that confirmed continuous infection control and the exudate absorption property of this non-leaching antimicrobial dressing over days of use.
"Expanding our NIMBUS antimicrobial technology to advanced wound care formats marks an important milestone for Quick-Med," said J. Ladd Greeno, Quick-Med's CEO. "We are excited to be partnering with Viridis. India's large wound care market represents a significant opportunity for Viridis to drive sales with our unique, value-added NIMBUS antimicrobial feature."
Dr. Dilip Mehta, CEO of Viridis BioPharma, commented, "We see this approval to manufacture and market Microfoam dressings that was developed by Viridis using NIMBUS Technology as a big step in improving wound care in India and other markets."
Quick-Med is seeking additional licensees for this new technology. NIMBUS foam production can be easily implemented at a company's current manufacturing location, or arrangements can be made for Viridis to provide finished product under a toll manufacturing agreement.
While NIMBUS antimicrobials remain at full strength, the active agent in most other antimicrobial technologies is depleted gradually while in use. These other antimicrobials carry the risk of irritation or interference with healing in products such as wound dressings and textile applications in which the treated material is next to or used on the skin.
The bonding of an antimicrobial to a substrate is a paradigm shift from the current state-of-the-art which fosters release of the active agent. The value of a non-leaching antimicrobial is that it does not allow depletion of the active agent which can lead to damage to human skin or tissue cells such that they can cause irritation, delay healing and possibly initiate the development of bacterial resistance.
Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received De Novo clearance from the US Food and Drug Administration in 2009 and has been commercialized in traditional wound care applications. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by twelve U.S. patents and patents pending and 24 foreign counterparts. Additional applications under development include other advanced wound dressings, medical adhesives, and catheters.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing proprietary, broad-based technologies for infection prevention and control in the consumer and healthcare markets. In addition to NIMBUS, Quick-Med's Stay Fresh® technology provides highly durable antimicrobial protection for laundered apparel and other textile applications and its NimbuDerm™ technology is being developed as a long-lasting hand sanitizer. For more information, see: www.quickmedtech.com.
The Quick-Med Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8260
About Viridis BioPharma Pvt. Ltd
Through strategic associations with international pharmaceutical and biopharma companies, Viridis BioPharma Pvt. Ltd. commercializes products with therapeutic efficacy and growth potential in the Indian subcontinent and delivers a range of clinically-proven products to enable people to live better and more active lives. Viridis currently manufactures and markets a number of medical devices for companies, manufactured under license from B. Braun, American BioTech Labs, and Bhabha Atomic Research Center (BARC). For more information, see: www.viridisbiopharma.com
© 2012 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® and Stay Fresh® are registered trademarks and NimbuDerm™ is a trademark of Quick-Med Technologies, Inc. Microgauze™ and Microfoam™ are trademarks of Viridis BioPharma Pvt. Ltd.
Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.
CONTACT: Quick-Med Technologies J. Ladd Greeno, CEO (888) 835.2211 Ext 102 email@example.com